NCT03387020 - Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 13, 2018

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions

CNS Embryonal Tumor, Not Otherwise SpecifiedMalignant GliomaRecurrent Atypical Teratoid/Rhabdoid TumorRecurrent Childhood EpendymomaRecurrent Diffuse Intrinsic Pontine GliomaRecurrent MedulloblastomaRefractory Diffuse Intrinsic Pontine Glioma

Interventions

DRUG

Everolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Ribociclib

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

20892

National Cancer Institute Pediatric Oncology Branch, Bethesda

30322

Children's Healthcare of Atlanta, Atlanta

38105

Pediatric Brain Tumor Consortium, Memphis

St. Jude Children Research Hospital, Memphis

45229

Cincinnati Children Hospital Medical Center, Cincinnati

77030

Texas Children's Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90026

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children Hospital Stanford University, Palo Alto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK